ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,681 to 4,700 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Treatment Group vs Control Group: Cardiovascular Mortality or Unplanned Hospitalisation/Prolongation of Hospitalisation for Worsening Heart Failure345 of 666

317 of 659

3.7 points

-1.7 to 9.0

1,325NCT00733343

Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure

Treatment Group vs Control Group: First Survived Resuscitation for Any Reason (Evaluation Will Also be Made by the ERC)25 of 666

19 of 659

0.9 points

-1.1 to 2.9

1,325NCT00733343

Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure

Treatment Group vs Control Group: Non-cardiovascular Death33 of 666

35 of 659

-0.4 points

-2.8 to 2.1

1,325NCT00733343

Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure

Treatment Group vs Control Group: All Cause Mortality or All Cause Unplanned Hospitalisation/Prolongation of Hospitalisation482 of 666

465 of 659

1.8 points

-3.0 to 6.7

1,325NCT00733343

Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure

Treatment Group vs Control Group: Unplanned Hospitalisation/Prolongation of Hospitalisation Due to Worsening of Heart Failure287 of 666

272 of 659

1.8 points

-3.5 to 7.1

1,325NCT00733343

Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure

Treatment Group vs Control Group: Death From Any Cause232 of 666

193 of 659

5.5 points

0.5 to 10.5

1,325NCT00733343

Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure

Treatment Group vs Control Group: All Cause Mortality or Unplanned Hospitalisation/Prolongation of Hospitalisation for Worsening Heart Failure360 of 666

335 of 659

3.2 points

-2.2 to 8.6

1,325NCT00733343

Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure

Treatment Group vs Control Group: deaths from any cause232 of 666

193 of 659

5.5 points

0.5 to 10.5

1,325NCT00733343

Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure

Treatment Group vs Control Group: Adequate Shock in Patients With ICD (Evaluation of Appropriateness Will Also be Made by the Endpoint Review Committee, ERC), Long-Term Atrial Defibrillator Insertion or Cardiovascular Death45 of 666

65 of 659

-3.1 points

-6.1 to -0.1

1,325NCT00733343

Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure

Treatment Group vs Control Group: Cardiovascular Death199 of 666

158 of 659

5.9 points

1.1 to 10.6

1,325NCT00733343

Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure

Treatment Group vs Control Group: serious adverse events482 of 666

465 of 659

1.8 points

-3.0 to 6.7

1,325NCT00733343

Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure

Restrictive vs Liberal: A Composite Endpoint of Cardiac Complications (Other Than MI) at 90 Days Post-randomization: Cardiac Complications Include New Cardiac Arrhythmias That Necessitate New Treatment, New or Worsening Congestive Heart Failure, and Non Fatal Cardiac Arrest67 of 678

38 of 647

4.0 points

1.1 to 6.9

1,325NCT03229941

Transfusion Trigger After Operations in High Cardiac Risk Patients

PP (Per Protocol) vs ITT (Intention to Treat): Number of Participants With Technical Success630 of 632

690 of 692

-0.0 points

-0.9 to 0.8

1,324NCT02536378

POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE

PP (Per Protocol) vs ITT (Intention to Treat): Number of Participants With Procedural Success630 of 632

690 of 692

-0.0 points

-0.9 to 0.8

1,324NCT02536378

POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE

PP (Per Protocol) vs ITT (Intention to Treat): Number of Participants With Acute Device Success630 of 632

690 of 692

-0.0 points

-0.9 to 0.8

1,324NCT02536378

POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE

PP (Per Protocol) vs ITT (Intention to Treat): deaths from any cause1 of 632

3 of 692

-0.3 points

-1.1 to 0.5

1,324NCT02536378

POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE

PP (Per Protocol) vs ITT (Intention to Treat): Number of Participants in Which a Cranial Nerve Injury Occurred8 of 632

10 of 692

-0.2 points

-1.5 to 1.2

1,324NCT02536378

POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE

PP (Per Protocol) vs ITT (Intention to Treat): serious adverse events27 of 632

14 of 692

2.2 points

0.4 to 4.3

1,324NCT02536378

POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE

A+AVD vs ABVD: Number of Participants With Abnormal Clinical Laboratory Values662 of 662

658 of 659

0.2 points

-0.4 to 0.9

1,321NCT01712490

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

A+AVD vs ABVD: deaths from any cause9 of 662

13 of 659

-0.6 points

-2.1 to 0.8

1,321NCT01712490

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=235"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=235

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00733343-8fe5a240",
        "title": "Treatment Group vs Control Group: Cardiovascular Mortality or Unplanned Hospitalisation/Prolongation of Hospitalisation for Worsening Heart Failure",
        "summary": "345 of 666 against 317 of 659; risk difference 3.7 points, 95% interval -1.7 to 9.0; NCT00733343, Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure",
        "record": "/library/comparisons/NCT00733343-8fe5a240",
        "nct_id": "NCT00733343",
        "kind": "outcome",
        "participants": 1325,
        "risk_difference": {
          "value": 0.036986151553678126,
          "lower": -0.01681776158141482,
          "upper": 0.09048844657312094
        },
        "group_1": "345 of 666",
        "group_2": "317 of 659",
        "difference": "3.7 points",
        "interval": "-1.7 to 9.0",
        "trial_title": "Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure"
      },
      {
        "id": "NCT00733343-a9b30798",
        "title": "Treatment Group vs Control Group: First Survived Resuscitation for Any Reason (Evaluation Will Also be Made by the ERC)",
        "summary": "25 of 666 against 19 of 659; risk difference 0.9 points, 95% interval -1.1 to 2.9; NCT00733343, Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure",
        "record": "/library/comparisons/NCT00733343-a9b30798",
        "nct_id": "NCT00733343",
        "kind": "outcome",
        "participants": 1325,
        "risk_difference": {
          "value": 0.0087059745633342,
          "lower": -0.011092006015265901,
          "upper": 0.028828951400611737
        },
        "group_1": "25 of 666",
        "group_2": "19 of 659",
        "difference": "0.9 points",
        "interval": "-1.1 to 2.9",
        "trial_title": "Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=236",
  "request_id": "Qh4BIeiNojJLRllt"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

Instruments

The conductscience.com catalog

One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.

Drugs and targets

Open Targets

One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.

Diseases

Open Targets

One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.

Companies

ClinicalTrials.gov

One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.

Cell lines

Cellosaurus

One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.

Journal index

PubMed and NLM's journal list

One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?